A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody

Published: 09-10-2018
Last updated: 10-01-2025

Study Objectives:* To monitor the long-term safety profile of NI-0501* To assess HLH patients* survival after NI-0501 treatment* To assess duration of response to NI-0501 treatment (i.e. maintenance of HLH control)* To assess post-HSCT outcome...

Ethical review	Approved WMO
Status	Will not start
Health condition type	Autoimmune disorders
Study type	Observational invasive

Summary

ID

NL-OMON48933

Source
ToetsingOnline

Brief title
NI-0501-05

Condition

- Autoimmune disorders

Synonym
Systemic Juvenile Idiopathic Arthritis, Systemic juvenile rheumatoid Arthritis

Research involving
Human

Sponsors and support

Primary sponsor: Swedish Orphan Biovitrum AG

Source(s) of monetary or material Support: Swedish Orphan Biovitrum AG

Intervention

Keyword: NI-0501, systemic Juvenile Idiopathic Arthritis

Outcome measures

Primary outcome

Study Parameters: * Vital signs, including body temperature

* Physical examination, including liver and spleen sizes

* Laboratory parameters: complete blood count, coagulation tests (aPTT, PT,

d-Dimers and fibrinogen), ferritin,CRP, LDH, glucose, triglycerides, ,

liver(alanine aminotransferase, aspartate aminotransferase, gamma glutamyl

transferase, total bilirubin and alkaline phosphatases) and renal function

tests (creatinine, albumin, urea)

* Pharmacokinetics: circulating NI-0501 concentration

* Pharmacodynamics: circulating IFNγ levels, CXCL9, CXCL10 and exploratory

markers of disease activity (e.g. sCD25)

* Anti-drug antibodies (ADAs).

Secondary outcome

N/A

Study description

Background summary

Macrophage Activation Syndrome (MAS) is a secondary form of HLH often observed in patients
suffering from a rheumatic disease, such as systemic Juvenile Idiopathic Arthritis (sJIA) and Systemic

Lupus Erythematosus (SLE). MAS, like HLH, is characterized by sustained immune cell activation and an associated cytokine storm of pro-inflammatory cytokines with overproduction of IFNγ and other cytokines.

NI-0501 has been selected because it inactivates a protein called interferon gamma (IFNγ) which is believed to be responsible for the inflammation and tissue damage in MAS patients. Therefore, by neutralizing IFNγ, the inflammation present in the body may be halted, stopping organ damage and restoring a healthier condition.

Beyond the demonstration of the safety, tolerability and efficacy of NI-0501 as induction treatment
for HLH and as treatment for MAS, there is a need to establish the mid- and long-term safety of NI-
0501 treatment and its influence on survival of patients.

Currently, 2 interventional studies are ongoing: an open-label Phase 2/3 study in patients with pHLH
(protocol NI-0501-04) and a pilot study in MAS in sJIA patients (protocol NI-0501-06).
In addition, NI-0501 has been administered under a compassionate use treatment protocol to HLH
patients that exhausted all available therapeutic options.
Study NI-0501-05 allows a systematic collection of long-term data in patients previously exposed to
NI-0501 during the course of the studies mentioned above (and potentially other studies not yet
ongoing) or who have received NI-0501 in compassionate use.

This is an international multicentre long-term follow-up study of HLH patients who have received at
least one dose of NI-0501 in the context of a previous NI-0501 clinical study in which no long-term
follow-up is already planned.

Study objective

Study Objectives:
* To monitor the long-term safety profile of NI-0501
* To assess HLH patients* survival after NI-0501 treatment
* To assess duration of response to NI-0501 treatment (i.e. maintenance of HLH control)
* To assess post-HSCT outcome measures, if applicable
* To assess background disease activity, in patients with secondary forms of HLH
* To study the elimination profile of NI-0501
* To evaluate the pharmacodynamic (PD) effects (levels of circulating Total IFNγ, CXCL9, CXCL10)

* To assess the profile of relevant HLH biomarkers, e.g., sCD25
* To assess the immunogenicity of NI-0501.

Study design

long-term follow-up of HLH patients who
received treatment with NI-0501

Study burden and risks

To date, NI-0501 has been given to 14 healthy adult volunteers and more than 50 patients with HLH. No safety concerns have so far been identified and no long term effect has been attributed to NI-0501. Certain risks related to it may still present as long as NI-0501 is detectable. Subjects participating in this long-term follow-up study will ensure that the medical condition and any effects of NI-0501 are monitored longer. and that his/her study doctor can take appropriate actions if needed. Data collected could help other patients with the same type of disease in the near future.

Contacts

Public
Swedish Orphan Biovitrum AG

Chemin des Aulx 12
Plan-les-Ouates 1228
CH
Scientific
Swedish Orphan Biovitrum AG

Chemin des Aulx 12
Plan-les-Ouates 1228
CH

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adolescents (12-15 years)
Adolescents (16-17 years)
Children (2-11 years)

Inclusion criteria

1. Having received at least one dose of NI-0501 during a previous NI-0501 study or under a compassionate use (CU) treatment protocol.
2. Informed Consent signed by the patient or the patient*s legal representative(s), as applicable, with the assent of patients who are legally capable of providing it.

Exclusion criteria

Please see inclusion criteria.

Study design

Design

Study phase:	2
Study type:	Observational invasive
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Will not start
Enrollment:	3
Type:	Anticipated

Medical products/devices used

Product type:	Medicine
Brand name:	EMAPALUMAB
Generic name:	NI-0501

Ethics review

Approved WMO Date:	09-10-2018
Application type:	First submission
Review commission:	METC NedMec
Approved WMO Date:	26-09-2019
Application type:	First submission
Review commission:	METC NedMec
Approved WMO Date:	15-01-2020
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO Date:	16-01-2020
Application type:	Amendment
Review commission:	METC NedMec

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2012-005753-23-NL
ClinicalTrials.gov	NCT02069899
CCMO	NL65288.041.18

Study results

Results posted: 21-03-2022

Summary results
Trial never started

First publication
08-03-2022